{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brimonidine%2C+timolol",
    "query": {
      "intervention": "brimonidine, timolol"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brimonidine%2C+timolol&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T10:13:20.456Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00651612",
      "title": "Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Concurrent brimonidine 0.2% and 0.5% timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 604,
      "start_date": "2005-11",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651612"
    },
    {
      "nct_id": "NCT00332345",
      "title": "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "brimonidine/timolol fixed combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "1999-07",
      "completion_date": "1999-08",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00332345"
    },
    {
      "nct_id": "NCT00869141",
      "title": "Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 52,
      "start_date": "2009-03",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2015-12-30",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00869141"
    },
    {
      "nct_id": "NCT00652106",
      "title": "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine 0.2% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 432,
      "start_date": "2003-06",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00652106"
    },
    {
      "nct_id": "NCT00800540",
      "title": "Circadian Ocular Perfusion Pressure and Ocular Blood Flow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2009-02",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-03-22",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00800540"
    },
    {
      "nct_id": "NCT03323164",
      "title": "Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma; Drugs",
        "Normal Tension Glaucoma",
        "Primary Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Timolol Maleate",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 35,
      "start_date": "2017-07-10",
      "completion_date": "2020-05-30",
      "has_results": true,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03323164"
    },
    {
      "nct_id": "NCT00811850",
      "title": "Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-12",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811850"
    },
    {
      "nct_id": "NCT02167035",
      "title": "Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Combigan Two Times Daily (BID)",
          "type": "DRUG"
        },
        {
          "name": "Simbrinza Three Times Daily (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornerstone Health Care, PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-08",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2018-10-24",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02167035"
    },
    {
      "nct_id": "NCT00698945",
      "title": "Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Istalol and Optive",
          "type": "DRUG"
        },
        {
          "name": "Alphagan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-06",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2008-12-04",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Petaluma, California",
      "locations": [
        {
          "city": "Petaluma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698945"
    },
    {
      "nct_id": "NCT06883123",
      "title": "Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Simbrinza 0.2%-1% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Rocklatan 0.02%-0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Cosopt PF 2%-0.5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prairie Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-05-14",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-16T10:13:20.456Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883123"
    }
  ]
}